News

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...
Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...
Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...
A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.
Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...
The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...
Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...
If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...
The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts ...